Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Gains from Investment Securities (2020 - 2023)

Ovid Therapeutics (OVID) has disclosed Gains from Investment Securities for 4 consecutive years, with $12000.0 as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Gains from Investment Securities changed N/A year-over-year to $12000.0, compared with a TTM value of $12000.0 through Sep 2024, up 200.0%, and an annual FY2022 reading of $15.8 million, up 46.54% over the prior year.
  • Gains from Investment Securities was $12000.0 for Q4 2023 at Ovid Therapeutics, up from -$12000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $15.8 million in Q2 2022 and bottomed at -$12000.0 in Q1 2023.
  • Average Gains from Investment Securities over 4 years is $1.7 million, with a median of $11000.0 recorded in 2020.
  • The sharpest move saw Gains from Investment Securities surged 3962.55% in 2022, then plummeted 378.75% in 2023.
  • Year by year, Gains from Investment Securities stood at $415526.0 in 2020, then dropped by 6.48% to $388610.0 in 2021, then soared by 3962.55% to $15.8 million in 2022, then crashed by 99.92% to $12000.0 in 2023.
  • Business Quant data shows Gains from Investment Securities for OVID at $12000.0 in Q4 2023, -$12000.0 in Q1 2023, and $15.8 million in Q2 2022.